#pharmaceuticals

Novo Nordisk's CagriSema disappoints in trials against Eli Lilly's obesity treatments. Analysis of the trillion-dollar market battle and implications for patients and investors.

Eli Lilly stockpiles $1.5 billion of oral Zepbound ahead of FDA approval, signaling confidence in weight-loss pill market disruption

Despite GLP-1 drugs like Ozempic showing dramatic individual results, national obesity rates remain stubbornly unchanged. We examine why the weight-loss revolution hasn't reached population-level statistics.

AstraZeneca forecasts steady 2026 growth driven by surging cancer drug demand. We analyze the investment implications and what this means for healthcare costs.

Danish pharma giant Novo Nordisk saw $50 billion wiped off its market value as competition threatens its dominance in the lucrative obesity drug market.

While Novo Nordisk's stock plummets 17% on weak 2026 outlook, Eli Lilly soars 8% with explosive growth. The weight loss drug market crown is changing hands as scale trumps innovation.

Merck and Pfizer earnings reveal the pharmaceutical industry's delicate balance between blockbuster dependency and pipeline innovation. What lies beneath the solid but unspectacular results?

China could become the first market to approve a fully AI-designed drug in 2026, marking a seismic shift in pharmaceutical development as the country transforms from generic manufacturer to innovation powerhouse.

Chai Discovery's $130M raise at a $1.3B valuation isn't a funding story. It's a signal that elite AI talent is targeting pharma's core business model.